Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DraftKings Inc (DKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DraftKings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while DraftKings Inc trades at $25.22 (market cap $12.05B). The key difference: DraftKings Inc is far larger — about 2.4× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | DKNG | |
|---|---|---|
Market Cap | $5.06B | $12.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $48.23 |
52-Week Low | $20.06 | $20.72 |
Enterprise Value | $4.18B | $12.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
DraftKings (DKNG) trades at $24.03, up 8.39% today, but remains under pressure with a bearish technical signal. Recent Q2 2026 earnings missed expectations, with an EPS loss of $0.14 versus a $0.02 profit forecast. Revenue grew to $6.05 billion in 2025, but net income margins are negative. Analyst consensus is bullish with a $33.86 price target, though news highlights competition from prediction markets and promotional costs.
The outlook is mixed: strong revenue growth and positive operating cash flow support long-term potential, but profitability challenges and competitive threats pose risks. Upside depends on execution in new markets and cost management, while investor sentiment is cautious amid recent earnings misses and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →
